Biognosys AG

www.biognosys.com

We believe that the decoding of the proteome will impact life science more than the genome revolution a decade ago. Biognosys provides innovative services and products for protein discovery and quantification using cutting edge technology. We strive to be the company that provides the best possible solutions to support researchers in their protein analysis needs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research, Diagnostics

XILIO THERAPEUTICS RELEASES PRELIMINARY RESULTS OF XTX101 PHASE 1 TRIAL

Globenewswire | May 26, 2023

news image

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced preliminary data from its Phase 1 clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors. “We are encouraged by the preliminary data from the Phase 1 trial for XTX101 showing evidence of tumor-selective ...

Read More

MedTech, Industrial Impact

RIBBON BIOLABS REACHES KEY MILESTONE WITH AUTOMATION OF INFINISYNTHTM PLATFORM FOR COMMERCIAL-SCALE, UNLIMITED LENGTH DNA SYNTHESIS

Ribbon Biolabs | December 21, 2022

news image

Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...

Read More

Cell and Gene Therapy

TEVOGEN BIO™ FURTHER STRENGTHENS IP PORTFOLIO WITH ADDITIONAL PATENT FOR METHOD OF PREPARING ITS INVESTIGATIONAL SARS-COV-2 SPECIFIC T CELL THERAPY

Tevogen Bio | January 13, 2022

news image

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent abi...

Read More

Industrial Impact

CELLARITY EXPANDS LEADERSHIP TEAM TO CONTINUE EVOLUTION OF A BREAKTHROUGH PLATFORM TO ENCODE BIOLOGY AND PURPOSEFULLY CREATE NEW MEDICINES

Cellarity | February 11, 2022

news image

Cellarity, a life sciences company founded by Flagship Pioneering to encode and simulate human biology to reimagine the way we create medicines, announced today the expansion of its executive leadership team with three key appointments. As Chief Scientific Officer, Laurens Kruidenier, Ph.D., will lead the continued evolution of Cellarity’s platform and pipeline and oversee cross functional integration across all aspects of computation, drug creation, and optimization. As Chief People Offic...

Read More
news image

Research, Diagnostics

XILIO THERAPEUTICS RELEASES PRELIMINARY RESULTS OF XTX101 PHASE 1 TRIAL

Globenewswire | May 26, 2023

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced preliminary data from its Phase 1 clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors. “We are encouraged by the preliminary data from the Phase 1 trial for XTX101 showing evidence of tumor-selective ...

Read More
news image

MedTech, Industrial Impact

RIBBON BIOLABS REACHES KEY MILESTONE WITH AUTOMATION OF INFINISYNTHTM PLATFORM FOR COMMERCIAL-SCALE, UNLIMITED LENGTH DNA SYNTHESIS

Ribbon Biolabs | December 21, 2022

Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...

Read More
news image

Cell and Gene Therapy

TEVOGEN BIO™ FURTHER STRENGTHENS IP PORTFOLIO WITH ADDITIONAL PATENT FOR METHOD OF PREPARING ITS INVESTIGATIONAL SARS-COV-2 SPECIFIC T CELL THERAPY

Tevogen Bio | January 13, 2022

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent abi...

Read More
news image

Industrial Impact

CELLARITY EXPANDS LEADERSHIP TEAM TO CONTINUE EVOLUTION OF A BREAKTHROUGH PLATFORM TO ENCODE BIOLOGY AND PURPOSEFULLY CREATE NEW MEDICINES

Cellarity | February 11, 2022

Cellarity, a life sciences company founded by Flagship Pioneering to encode and simulate human biology to reimagine the way we create medicines, announced today the expansion of its executive leadership team with three key appointments. As Chief Scientific Officer, Laurens Kruidenier, Ph.D., will lead the continued evolution of Cellarity’s platform and pipeline and oversee cross functional integration across all aspects of computation, drug creation, and optimization. As Chief People Offic...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us